- Design
- Descriptive observational study of pharmacovigilance enquiries
- Population
- 2,473 breastfeeding-related enquiries to the Lyon centre, 2019–2023
- Primary outcome
- Recommendation given
- Effect
- Breastfeeding supported in 87%; unfavourable advice in 13%
The Lyon pharmacovigilance centre reviewed all 2,473 enquiries it received between 2019 and 2023 about medicines during breastfeeding, about 500 a year. Mothers themselves asked 44% of the questions, allied professionals 29% and specialists 25%.
The centre supported breastfeeding in 87% of cases, sometimes with conditions such as infant monitoring, a dose change or timing doses around feeds. Only 13% led to advice to stop either the drug or breastfeeding, for a formal contraindication, too little benefit or too little safety data. Taking several medicines at once (35% of cases) made restrictive advice more likely. Adverse effects reported in infants were rare and not serious. Chronic treatments — antihypertensives, antiepileptics, psychotropics — made up 36% of enquiries.
This is a descriptive service audit, not a safety study, but it reflects how often 'stop breastfeeding' is given as a reflex answer when a considered one would allow both. Specialist lactation drug resources exist precisely to avoid that.
- Check a lactation drug database before advising a mother to stop breastfeeding
- Prefer drugs with established breastfeeding data, low milk transfer and short half-lives
- Time doses just after a feed where the drug's half-life makes that useful
- Review the whole regimen when a mother takes several drugs, since combinations raise risk
- Ask about infant age and prematurity, which change how much exposure matters
Why it matters
Unnecessary advice to stop breastfeeding is a common, avoidable harm of prescribing.
Don't overread it
These are advice outcomes from one centre, not measured infant drug levels or long-term follow-up.
The statistics, in plain English
The 87% figure describes what the centre recommended, not proof that every drug was safe; it shows how rarely a considered review found a reason to stop.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free